Monday, October 20, 2014

GeneNews’ IDL adds blood test for breast cancer prediction

GeneNews’ IDL adds blood test for breast cancer prediction

October 14, 2014 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) has in-licensed two biomarker assays – sphingotest pro-NT and sphingotest pro-ENK – that aid physicians in identifying those females at highest risk for breast cancer in the general population. Both tests were developed by sphingotec GmbH of Germany, a biomarker assay developer, which has recently expanded in the U.S. GeneNews expects to […]

GeneNews Q2 JV lab test volumes more than triple sequentially

GeneNews Q2 JV lab test volumes more than triple sequentially

August 8, 2014 by · Leave a Comment 

Tweet GeneNews’ (TSX:GEN) U.S. joint venture, Innovative Diagnostic Laboratory (IDL), processed 46,051 tests in the second quarter, up more than threefold sequentially from the 14,680 tests processed in the first quarter this year. “So far, that growth has continued into the third quarter,” GeneNews executive chairman James Howard-Tripp said in a statement. IDL’s menu of […]

GeneNews’ IDL jv highlighted on CEO Clips

GeneNews’ IDL jv highlighted on CEO Clips

July 3, 2014 by · Leave a Comment 

Tweet James Howard-Tripp, executive chairman of GeneNews (TSX:GEN), has been featured on Business Television’s CEO Clips discussing the company’s new U.S. joint venture, Innovative Diagnostic Laboratory, or IDL. IDL’s mission is to provide a comprehensive menu of advanced blood tests that aid in early cancer detection, guide cancer treatment protocols, and monitor remission and recurrence. […]

GeneNews in $7.2-million private placement

GeneNews in $7.2-million private placement

July 2, 2014 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) is proposing to complete a non-brokered private placement of up to seven million new common shares at a price of $1.03 a share (a 12.5% discount to the five-day VWAP) for gross proceeds of up to $7.2-million. Proceeds will be used for general working capital purposes. Closing is set for July 7. […]

PHI test included in updated NCCN Guidelines

PHI test included in updated NCCN Guidelines

May 23, 2014 by · Leave a Comment 

Tweet Beckman Coulter’s Prostate Health Index (PHI), which is offered in the U.S. by GeneNews’ (TSX:GEN) Innovation Diagnostic Lab (IDL) joint venture, has been recommended by the National Comprehensive Cancer Network (NCCN) as a blood test to improve specificity for prostate cancer detection in its recently updated Clinical Practice Guidelines in Oncology (NCCN Guidelines) for […]

GeneNews’ IDL off to flying start

GeneNews’ IDL off to flying start

May 20, 2014 by · Leave a Comment 

Tweet GeneNews’ (TSX:GEN) recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL), took a huge step forward in the first quarter in its goal of becoming a leader in molecular diagnostics and personalized medicine. “With a successful limited scale launch of IDL in the fourth quarter of 2013, full scale-up activities began in the first […]

GeneNews IDL JV posts big jumps in tests processed

GeneNews IDL JV posts big jumps in tests processed

May 15, 2014 by · Leave a Comment 

Tweet GeneNews’ (TSX:GEN) recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL), has reported a 346% sequential jump in tests processed during the first quarter, compared with the 2013 fourth quarter. IDL processed 14,680 tests at its CLIA-approved lab in Richmond, VA during the initial quarter this year and “growth is expected to continue throughout the […]

GeneNews’ JV IDL launches Beckman Coulter’s phi test across U.S.

GeneNews’ JV IDL launches Beckman Coulter’s phi test across U.S.

April 24, 2014 by · Leave a Comment 

Tweet GeneNews’ (TSX:GEN) recently formed joint venture, Innovative Diagnostic Laboratory, has added Beckman Coulter Diagnostics’ Prostate Health Index (phi) to its menu of advanced cancer assays and has initiated a commercial roll out of the groundbreaking test across the U.S. The phi test is a simple, non-invasive blood test that is three times more specific […]

Zacks ups GeneNews price target to $3

Zacks ups GeneNews price target to $3

March 6, 2014 by · Leave a Comment 

Tweet Zacks Investment Research has raised its price target for “outperform-rated” GeneNews (TSX:GEN) to $3 from $2, saying revenue growth will accelerated in 2014 and beyond from a recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL). Shares of GeneNews closed at $1.09 on Wednesday. “Specifically, we estimate revenue from IDL will be $2.6-million [in […]

GeneNews JV in U.S.-wide rollout of ColonSentry, adds new test

GeneNews JV in U.S.-wide rollout of ColonSentry, adds new test

January 21, 2014 by · Leave a Comment 

Tweet GeneNews’ (TSX:GEN) recently formed joint venture, Innovative Diagnostic Laboratory, or IDL, is initiating the full-scale rollout of the ColonSentry test throughout the U.S. and adding EarlyCDT-Lung – a simple blood test that aids physicians in risk assessment and the early detection of lung cancer in high-risk, asymptomatic patients – to its offering. “I am pleased […]

Next Page »

Email Newsletters with Constant Contact
Google+